Lung Cancer

Immune checkpoint inhibitors were generally well tolerated and may be a viable treatment option for patients with HIV infection and advanced-stage cancer.

A cancer gene panel using blood may be a cost-effective way of testing the quantity of mutations found in tumors of patients with non-small cell lung cancer.

A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non-small cell lung cancer at a similar rate but faster than tissue genotyping.

Supreme Court Justice Ruth Bader Ginsburg has survived three types of cancer and has not missed a day of work.

From 240 million-year-old dinosaur tumors to today's top performers and athletes, here is a quick overview of what is making headlines in the cancer space.

One expert weighs in on the use of new immunotherapy agents and combinations in treating non-small cell lung cancer.

The Food and Drug Administration has accepted Roche’s supplemental biologics license application for Tecentriq (atezolizumab) plus chemotherapy for the frontline treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumor aberrations.

The FDA has granted a priority review designation to a supplemental biologics license application (sBLA) for Tecentriq (atezolizumab) for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

Given their proximity to both patients and information, lung cancer advocacy groups are in a good position to help better educate patients and physicians about the benefits of biomarker testing.

Many patients with lung cancer may experience side effects, such as fatigue and shortness of breath, that can prevent them from exercising. However, for the first time, new research findings showed benefits from exercise in those with advanced disease.

The Food and Drug Administration (FDA) granted accelerated approval to Lorbrena (lorlatinib) for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) who progressed on one or more ALK tyrosine kinase inhibitor (TKI), according to Pfizer, the drug’s manufacturer.

With the click of a button, patients can pave the way for lung cancer research, too.

Here are the top 5 CURE stories for October 2018.

The immunotherapy agent received approval for the treatment of metastatic squamous non-small cell lung cancer.

A high dose of precision radiation could drastically increase the survival rates of patients with metastatic cancer, and double the time patients live without cancer growth, according to study results presented at the 60th Annual Meeting of the American Society for Radiation Oncology.

Patients with head and neck cancer appeared to be receptive to lung cancer screening, according to recent research performed at the University of Iowa Hospitals and Clinics.

As marijuana use continues to increase across the US – and become legalized in more states – understanding the potential negative health effects is paramount.

Patients with the disease reported increased feelings of stigmatization, and results also showed that patients are viewed or treated differently than those with other cancer types.

Long-term opioid use is more prevalent among patients treated with invasive surgical techniques for early-stage non-small cell lung cancer than those who undergo minimally-invasive surgery.

While the living rooms take place in the ALCF's California headquarters, people around the world can tune in to the live stream, where they can participate and ask questions as if they were actually there.

The Food and Drug Administration (FDA) has approved Vizimpro (dacomitinib) for the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations, according to Pfizer, the manufacturer of the pan-human EGFR tyrosine kinase inhibitor (TKI).